805 related articles for article (PubMed ID: 22703868)
1. Dyskinesias in patients with Parkinson's disease: effect of the leucine-rich repeat kinase 2 (LRRK2) G2019S mutation.
Yahalom G; Kaplan N; Vituri A; Cohen OS; Inzelberg R; Kozlova E; Korczyn AD; Rosset S; Friedman E; Hassin-Baer S
Parkinsonism Relat Disord; 2012 Nov; 18(9):1039-41. PubMed ID: 22703868
[TBL] [Abstract][Full Text] [Related]
2. The LRRK2 G2019S mutation in Ashkenazi Jews with Parkinson disease: is there a gender effect?
Orr-Urtreger A; Shifrin C; Rozovski U; Rosner S; Bercovich D; Gurevich T; Yagev-More H; Bar-Shira A; Giladi N
Neurology; 2007 Oct; 69(16):1595-602. PubMed ID: 17938369
[TBL] [Abstract][Full Text] [Related]
3. Motor progression of Parkinson's disease with the leucine-rich repeat kinase 2 G2019S mutation.
Yahalom G; Orlev Y; Cohen OS; Kozlova E; Friedman E; Inzelberg R; Hassin-Baer S
Mov Disord; 2014 Jul; 29(8):1057-60. PubMed ID: 24903616
[TBL] [Abstract][Full Text] [Related]
4. Genetic analysis for five LRRK2 mutations in a Sardinian parkinsonian population: importance of G2019S and R1441C mutations in sporadic Parkinson's disease patients.
Floris G; Cannas A; Solla P; Murru MR; Tranquilli S; Corongiu D; Rolesu M; Cuccu S; Sardu C; Marrosu F; Marrosu MG
Parkinsonism Relat Disord; 2009 May; 15(4):277-80. PubMed ID: 18805725
[TBL] [Abstract][Full Text] [Related]
5. Parkinson disease phenotype in Ashkenazi Jews with and without LRRK2 G2019S mutations.
Alcalay RN; Mirelman A; Saunders-Pullman R; Tang MX; Mejia Santana H; Raymond D; Roos E; Orbe-Reilly M; Gurevich T; Bar Shira A; Gana Weisz M; Yasinovsky K; Zalis M; Thaler A; Deik A; Barrett MJ; Cabassa J; Groves M; Hunt AL; Lubarr N; San Luciano M; Miravite J; Palmese C; Sachdev R; Sarva H; Severt L; Shanker V; Swan MC; Soto-Valencia J; Johannes B; Ortega R; Fahn S; Cote L; Waters C; Mazzoni P; Ford B; Louis E; Levy O; Rosado L; Ruiz D; Dorovski T; Pauciulo M; Nichols W; Orr-Urtreger A; Ozelius L; Clark L; Giladi N; Bressman S; Marder KS
Mov Disord; 2013 Dec; 28(14):1966-71. PubMed ID: 24243757
[TBL] [Abstract][Full Text] [Related]
6. LRRK2 mutations in Spanish patients with Parkinson disease: frequency, clinical features, and incomplete penetrance.
Gaig C; Ezquerra M; Marti MJ; Muñoz E; Valldeoriola F; Tolosa E
Arch Neurol; 2006 Mar; 63(3):377-82. PubMed ID: 16533964
[TBL] [Abstract][Full Text] [Related]
7. Penetrance estimate of LRRK2 p.G2019S mutation in individuals of non-Ashkenazi Jewish ancestry.
Lee AJ; Wang Y; Alcalay RN; Mejia-Santana H; Saunders-Pullman R; Bressman S; Corvol JC; Brice A; Lesage S; Mangone G; Tolosa E; Pont-Sunyer C; Vilas D; Schüle B; Kausar F; Foroud T; Berg D; Brockmann K; Goldwurm S; Siri C; Asselta R; Ruiz-Martinez J; Mondragón E; Marras C; Ghate T; Giladi N; Mirelman A; Marder K;
Mov Disord; 2017 Oct; 32(10):1432-1438. PubMed ID: 28639421
[TBL] [Abstract][Full Text] [Related]
8. A common leucine-rich repeat kinase 2 gene mutation in familial and sporadic Parkinson's disease in Russia.
Illarioshkin SN; Shadrina MI; Slominsky PA; Bespalova EV; Zagorovskaya TB; Bagyeva GKh; Markova ED; Limborska SA; Ivanova-Smolenskaya IA
Eur J Neurol; 2007 Apr; 14(4):413-7. PubMed ID: 17388990
[TBL] [Abstract][Full Text] [Related]
9. LRRK2 Gly2019Ser penetrance in Arab-Berber patients from Tunisia: a case-control genetic study.
Hulihan MM; Ishihara-Paul L; Kachergus J; Warren L; Amouri R; Elango R; Prinjha RK; Upmanyu R; Kefi M; Zouari M; Sassi SB; Yahmed SB; El Euch-Fayeche G; Matthews PM; Middleton LT; Gibson RA; Hentati F; Farrer MJ
Lancet Neurol; 2008 Jul; 7(7):591-4. PubMed ID: 18539535
[TBL] [Abstract][Full Text] [Related]
10. G2019S LRRK2 mutation in familial and sporadic Parkinson's disease in Russia.
Pchelina SN; Yakimovskii AF; Ivanova ON; Emelianov AK; Zakharchuk AH; Schwarzman AL
Mov Disord; 2006 Dec; 21(12):2234-6. PubMed ID: 17044089
[TBL] [Abstract][Full Text] [Related]
11. Higher frequency of certain cancers in LRRK2 G2019S mutation carriers with Parkinson disease: a pooled analysis.
Agalliu I; San Luciano M; Mirelman A; Giladi N; Waro B; Aasly J; Inzelberg R; Hassin-Baer S; Friedman E; Ruiz-Martinez J; Marti-Masso JF; Orr-Urtreger A; Bressman S; Saunders-Pullman R
JAMA Neurol; 2015 Jan; 72(1):58-65. PubMed ID: 25401981
[TBL] [Abstract][Full Text] [Related]
12. Prevalence and clinical features of common LRRK2 mutations in Australians with Parkinson's disease.
Huang Y; Halliday GM; Vandebona H; Mellick GD; Mastaglia F; Stevens J; Kwok J; Garlepp M; Silburn PA; Horne MK; Kotschet K; Venn A; Rowe DB; Rubio JP; Sue CM
Mov Disord; 2007 May; 22(7):982-9. PubMed ID: 17427941
[TBL] [Abstract][Full Text] [Related]
13. Motor and non-motor features of Parkinson's disease in LRRK2 G2019S carriers versus matched controls.
Gunzler SA; Riley DE; Chen SG; Tatsuoka CM; Johnson WM; Mieyal JJ; Walter EM; Whitney CM; Feng IJ; Owusu-Dapaah H; Mittal SO; Wilson-Delfosse AL
J Neurol Sci; 2018 May; 388():203-207. PubMed ID: 29627023
[TBL] [Abstract][Full Text] [Related]
14. Genetic analysis of LRRK2 mutations in patients with Parkinson disease.
Deng H; Le W; Guo Y; Hunter CB; Xie W; Huang M; Jankovic J
J Neurol Sci; 2006 Dec; 251(1-2):102-6. PubMed ID: 17097110
[TBL] [Abstract][Full Text] [Related]
15. Fall risk and gait in Parkinson's disease: the role of the LRRK2 G2019S mutation.
Mirelman A; Heman T; Yasinovsky K; Thaler A; Gurevich T; Marder K; Bressman S; Bar-Shira A; Orr-Urtreger A; Giladi N; Hausdorff JM;
Mov Disord; 2013 Oct; 28(12):1683-90. PubMed ID: 24123150
[TBL] [Abstract][Full Text] [Related]
16. MAPK-pathway activity, Lrrk2 G2019S, and Parkinson's disease.
White LR; Toft M; Kvam SN; Farrer MJ; Aasly JO
J Neurosci Res; 2007 May; 85(6):1288-94. PubMed ID: 17385669
[TBL] [Abstract][Full Text] [Related]
17. [Clinical features of LRRK2-associated Parkinson's disease].
Pchelina SN; Ivanova ON; Emel'ianov AK; Iakimovskiĭ AF
Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(12):56-62. PubMed ID: 22433811
[TBL] [Abstract][Full Text] [Related]
18. Frequency of LRRK2 mutations in early- and late-onset Parkinson disease.
Clark LN; Wang Y; Karlins E; Saito L; Mejia-Santana H; Harris J; Louis ED; Cote LJ; Andrews H; Fahn S; Waters C; Ford B; Frucht S; Ottman R; Marder K
Neurology; 2006 Nov; 67(10):1786-91. PubMed ID: 17050822
[TBL] [Abstract][Full Text] [Related]
19. A study of LRRK2 mutations and Parkinson's disease in Brazil.
Pimentel MM; Moura KC; Abdalla CB; Pereira JS; de Rosso AL; Nicaretta DH; Campos M; de Almeida RM; dos Santos JM; Bastos IC; Mendes MF; Maultasch H; Costa FH; Werneck AL; Santos-Rebouças CB
Neurosci Lett; 2008 Mar; 433(1):17-21. PubMed ID: 18201824
[TBL] [Abstract][Full Text] [Related]
20. Motor phenotype of LRRK2-associated Parkinson's disease: a Tunisian longitudinal study.
Nabli F; Ben Sassi S; Amouri R; Duda JE; Farrer MJ; Hentati F
Mov Disord; 2015 Feb; 30(2):253-8. PubMed ID: 25487881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
